Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

05. September 2017 07:00 ET | Quelle: pSivida Corp

pSivida Corp. to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Monday, September 11th

WATERTOWN, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye...
01. August 2017 07:00 ET | Quelle: pSivida Corp

pSivida to Present at Canaccord Genuity Growth Conference on August 10, 2017

WATERTOWN, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of ocular sustained release drug products and technologies for eye diseases,...
18. Juli 2017 07:00 ET | Quelle: pSivida Corp

Leading Retinal Specialists to Highlight pSivida’s Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences

WATERTOWN, Mass., July 18, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that three...
10. Juli 2017 16:01 ET | Quelle: pSivida Corp

pSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN® Improves pSivida’s Revenue Generation

WATERTOWN, Mass., July 10, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced an...
28. Juni 2017 07:00 ET | Quelle: pSivida Corp

pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson

WATERTOWN, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that...
22. Juni 2017 07:00 ET | Quelle: pSivida Corp

pSivida Submits Marketing Authorization Application (MAA) for Approval of Durasert™ Three-year Treatment for Posterior Segment Uveitis in the European Union

WATERTOWN, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, has submitted a Marketing...
13. Juni 2017 07:00 ET | Quelle: pSivida Corp

pSivida’s Durasert™ Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study

Highly Significant Difference Observed Between Durasert and Control Group in Primary Efficacy Analysis of Prevention of Uveitis Recurrence Conference Call Today at 4:30 p.m.ET WATERTOWN, Mass.,...
08. Mai 2017 09:15 ET | Quelle: pSivida Corp

Durasert™ Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months

Positive Data Presented at the Association for Research in Vision and Ophthalmology Annual Meeting pSivida Anticipates Reporting Top Line Results from the Second Pivotal Phase 3 Clinical Trial in...
04. Mai 2017 16:01 ET | Quelle: pSivida Corp

pSivida Corp. Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track

EU and US Calendar 2017 Registration Filing Milestones for Durasert™ for Posterior Segment Uveitis Remain on Schedule Conference Call and Webcast Today, May 4th, at 4:30 p.m. ET WATERTOWN,...
19. April 2017 16:01 ET | Quelle: pSivida Corp

pSivida Corp. to Report Third Quarter Fiscal Year 2017 Financial Results on Thursday, May 4th

WATERTOWN, Mass., April 19, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye...

Vorherige Seite